Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australi

Wells Fargo analyst Yanan Zhu upgrades Editas Medicine (NASDAQ:EDIT) from Equal-Weight to Overwei

The trial has received Human Research Ethics Committee (HREC) approval and completed the Clinical Tr

Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional L

Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) passed below its fifty day moving average dur

U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securit

Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with

Guggenheim analyst Debjit Chattopadhyay upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Bu

Veea shares surged 58% premarket on a NovaGen merger plan and $10M GeoNova investment, while other s

Bank of New York Mellon Corp purchased a new position in shares of Editas Medicine, Inc. (NASDAQ: ED

Editas Medicine NASDAQ: EDIT outlined its strategy as an in vivo gene-editing company and said it re

CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneer

Editas Medicine NASDAQ: EDIT is preparing to begin a first-in-human study of EDIT-401, an in vivo CR

Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and gene

BlackRock Inc. acquired a new stake in Editas Medicine, Inc. (NASDAQ: EDIT) in the undefined quarter

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneer

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str

Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared t

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.15) per share which beat the analyst

EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-c

Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning

Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery for

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneerin

Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative med

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneerin

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative med

CAMBRIDGE, Mass. , May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneeri

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-hu

The data is being presented this week at the 2026 Annual Meeting of the American Society of Gene and

Chardan Capital analyst Geulah Livshits maintains Editas Medicine (NASDAQ:EDIT) with a Buy and ra

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.26) per share which beat the analyst

Five abstracts have been accepted for presentation, including one oral presentation and two poster p

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

Jones Trading analyst Soumit Roy upgrades Editas Medicine (NASDAQ:EDIT) from Hold to Buy and anno

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.06) per share which beat the analyst

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transf

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a s

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potenti

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Editas Medicine (NASDAQ:EDIT) with

Wells Fargo analyst Yanan Zhu maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and rai